QUEBEC CITY, Feb. 14 /CNW Telbec/ - Advitech Inc. (“Advitech” or the “Company”) (TSX Venture Exchange: AVI) announces today that a second preclinical study conducted by Dr Charles Doillon, M.D, PhD from the Oncology and Molecular Endocrinology department of the Centre de Recherche du Centre Hospitalier de l’Université Laval (“CHUL”) has provided new indications of the wound healing properties of a milk devired fraction originating from the research work on its XP828L and IM technological platforms.
